Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer— is there a need for radioactive iodine therapy?
Authors:
- Iain J. NixonINIain J. Nixon
- Frank L. PalmerFPFrank L. Palmer
- Monica M. WhitcherMWMonica M. Whitcher
- Robert M. TuttleRTRobert M. Tuttle
- Ashok ShahaASAshok Shaha
- Snehal G. PatelSPSnehal G. Patel
- Jatin P. ShahJSJatin P. Shah
- Ian GanlyIGIan Ganly
- 1 December 2012
- Vol. 152 (6) , 1096-1105
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Thyroid lobectomy for treatment of well differentiated intrathyroid malignancySurgery, 2012
- Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapyCancer, 2011
- Application of post‐surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low‐risk papillary thyroid carcinomaHead & Neck, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Serum thyroglobulin determination in thyroid cancer patientsBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort StudyJournal of Nuclear Medicine, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomasJournal of Surgical Oncology, 2002
- A comparison of different staging systems predictability of patient outcomeCancer, 1997
- The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patientsThe Journal of Clinical Endocrinology & Metabolism, 1992